Authors
Latest:
The Possibility of Writing Information for Patient ComprehensionStephen Rosenberg, MD, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, discusses the possibility of writing information in a way that patients can understand.
Latest:
Carcinoid Syndrome Symptoms May Improve With Telotristat EtiprateA novel serotonin synthesis inhibitor, telotristat etiprate, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care treatments, an encouraging sign for an emerging class of drugs.
Latest:
Dr. Steven A. Fischkoff on Access to TIL Treatment for Patients With MelanomaFischkoff says the goal of Lion Biotechnologies is to utilize a central manufacturing facility where medical professionals can submit tumor samples of their patients, and received the proper TIL-based treatment back from the manufacturing facility.
Latest:
NovoTTF and Temozolomide for GlioblastomaSteven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses the combination of the Novo Tumor Treating Fields (NovoTTF) system and temozolomide for patients with glioblastoma.
Latest:
An Overview of EarlyR Gene Signature in the BIG-198 Trial for Breast CancerSteven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group 1-98 study.
Latest:
Comparing the Different Frontline Treatment Options in CLLSteven Coutre, MD, professor of medicine, Stanford University School of Medicine, discusses the benefits and drawbacks of the different frontline treatment options for chronic lymphocytic leukemia (CLL).
Latest:
The Importance of Molecular Profiling in Hematologic DiseasesSteven E. Coutre, MD, professor at the Stanford University Medical Center, discusses the importance of molecular profiling in hematologic diseases, including acute lymphoblastic leukemia.
Latest:
Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized SarcomaResearchers offer a review of the role of adjuvant or neoadjuvant chemotherapy, targeted therapy, and immunotherapy in localized soft tissue sarcoma.
Latest:
Dr. Steven Gore on Potential Negative Effects of Further Research into Azanucleoside CombinationsSteven D. Gore, MD, director of Hematologic Malignancies at Yale Cancer Center, talks about the risk of constantly testing azanucleoside combinations without significant results. Gore says that testing azanucleoside combinations that are not well planned may cause the medical community to overlook an effective combination due to fatigue of constant testing.
Latest:
Soft Tissue Sarcomas: Emerging and Novel ConceptsSoft tissue sarcomas are a rare and challenging group of malignancies of mesenchymal origin that have historically been treated with similar approaches.
Latest:
The Relationship Between Thyroid-Stimulating Hormone Levels and Outcomes From SELECTSteven I. Sherman, MD, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial.
Latest:
Rationale for Genetic Testing in Patients With Breast CancerSteven J. Katz, MD, MPH, discusses the benefits and challenges with genetic testing in patients with breast cancer.
Latest:
Precision Medicine Advances in Breast CancerSteven Katz, MD, professor, internal medicine, at the University of Michigan Medical School, discusses the major advances in precision medicine in the field of breast cancer.
Latest:
Dr. Steven Shak on the Results of the TAILORx Trial for Breast CancerShak says the study examined the prospective outcomes of 1626 women and showed that at 5 years, less than 1% of women had a distant recurrence.
Latest:
Exploring Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With AMLSudipto Mukherjee, MD, assistant staff, Gaussig Cancer Institute, Cleveland Clinic, discusses a study exploring eltrombopag to enhance platelet count recovery in elderly patients with acute myeloid leukemia (AML).
Latest:
Impact of Biosimilars on OncologySue Naeyaert, senior director of Biosimilars Policy, EMD Serono, discusses the long-term impact that biosimilars could potentially have on the field of oncology.
Latest:
Chemotherapy Administration and Survival in Soft Tissue SarcomaSujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses an analysis of chemotherapy administration and survival in soft tissue sarcoma.
Latest:
Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung CancerSukhmani Padda, MD, discusses the role of immunotherapy in patients with <em>EGFR</em>-positive non–small cell lung cancer.
Latest:
The Utility of the BRCAvantage TestSukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
Latest:
Treating Patients With RCC Who Progress Following Adjuvant TherapyThe expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.
Latest:
The Role of Stem-Cell Transplant in Multiple MyelomaSundar Jagannath, MD, director, Multiple Myeloma Program, Tisch Cancer Institute at Mount Sinai Hospital, discusses the role of stem-cell transplant in the management of multiple myeloma.
Latest:
Dr. Jagannath Discusses the STORM and STOMP Trials for Patients With Multiple MyelomaSundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses the STORM and STOMP clinical trials in patients with multiple myeloma.
Latest:
Hypertension Risk Among Cancer Patients Treated With Sunitinib: A Meta-analysis and Systematic ReviewSunitinib treatment is associated with a significantly increased risk of all-grade and high-grade hypertension.
Latest:
Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast CancerSunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses updated results of the phase III MONALEESA-2 trial of first-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer during the 2017 ASCO Annual Meeting.
Latest:
Evolving Standards of HER2-Positive Breast CancerSunil Verma, MD, MSEd, FRCPC, discusses evolving standards of early stage HER2-positive breast cancer.
Latest:
Value-Based Agreements Take Center Stage at COA SummitPressure on regulators to reduce healthcare costs could be a response to the estimated $1 trillion in US expenditures from poor care coordination, administrative burdens, and fraud, said Jeff Mortier, partner at Farragut Partners, during the Community Oncology Alliance Payer Exchange Summit.
Latest:
Panelists Highlight Ways to Ease Transition to Value-Based CareIn a panel discussion this morning during the Association of Community Cancer Center (ACCC)’s 44th Annual Meeting & Cancer Center Business Summit, experts stressed the importance of integrating team-based care to break silos and allow a continued care transition as the move continues toward value-based care.
